ISU College of Veterinary Medicine to Conduct a Study with Immunocidin® in the Treatment of Canine Hemangiosarcoma
NovaVive's anticancer immunotherapeutic for dogs will be evaluated in a clinical study at Iowa State University (ISU) College of Veterinary Medicine in the treatment of splenic hemangiosarcoma (in combination with chemo).
It's World Antibiotic Awareness Week and NovaVive is doing its part to help address the concern about antibiotic resistance by offering antibiotic alternatives for animals to the veterinary community and livestock/pet owners.
Amplimune® Receives Canadian OMRI Listing for Use in Organic Cattle Production
The Company's regulator-approved immunotherapy for calf scours, Amplimune®, has received an Organic Materials Review Institute (OMRI) Listing in Canada. This means that Amplimune may be used in organic cattle production.
NovaVive made two presentations at the World Buiatrics Congress in Sapporo, Japan today. Both presentations highlighted efficacy of MCWF in mature dairy cattle. More research is required, but these results are very promising.
NovaVive Inc. Signs AABEX Animal Health to Provide U.S. Marketing Services
NovaVive Inc. has signed a marketing services agreement with AABEX Animal Health for the U.S.A. AABEX is a new animal health sales and marketing company founded by Mark Hill, a seasoned industry professional from Merial Ltd.
Immunocidin® Demonstrates an Acceptable Safety Profile Following Intravenous Administration in Dogs and Cats with Various Malignancies
Dr. Jeannette Kelly, veterinary oncologist with Veterinary Cancer Care, presented data from a study of multiple IV administrations of Immunocidin® in dogs and cats with various malignancies at the ACVIM Forum last week.